Aspire Biopharma has agreed to acquire Dura Driver Control Systems for $30 million in cash, adding a business with over $200 million in 2025 revenue and more than $22 million in Adjusted EBITDA. The deal, expected to close in Q3 2026, diversifies Aspire’s profile beyond drug-delivery into automotive technology.
Aspire Biopharma has signed a definitive agreement to acquire 100% of Dura Driver Control Systems for $30 million in cash. Under the terms, Dura will become a wholly owned subsidiary upon closing in the third quarter of 2026, subject to customary conditions.
Dura generated more than $200 million in revenue and over $22 million in Adjusted EBITDA during fiscal 2025, operating 11 manufacturing facilities across North America, Europe and Asia. The acquisition provides immediate revenue generation, positive earnings and established customer contracts in the automotive sector.
The deal marks a transformational shift for Aspire, adding a substantial intellectual property portfolio of over 310 patents and relationships with major OEMs. It broadens the business mix from pharmaceutical and drug-delivery technology into vehicle electrification, safety systems and human-machine interfaces.
Aspire does not plan to raise new equity to complete the transaction, having secured a senior secured credit facility of up to $22.5 million to fund a significant portion of the purchase price. Integration planning is underway to align manufacturing operations and consolidate financial reporting post-close.
Finance
